Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

High pathologic misdiagnosis of cervical adenocarcinoma in situ.

Jordan SM, Chase DM, Watanabe T, Osann K, Monk BJ, Rutgers JK.

Eur J Gynaecol Oncol. 2013;34(5):446-9.

PMID:
24475580
2.

Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ.

Lea JS, Shin CH, Sheets EE, Coleman RL, Gehrig PA, Duska LR, Miller DS, Schorge JO.

Gynecol Oncol. 2002 Oct;87(1):129-32.

PMID:
12468353
3.
5.

Invasive adenocarcinoma of the cervix following LLETZ (large loop excision of the transformation zone) for adenocarcinoma in situ.

Kennedy AW, elTabbakh GH, Biscotti CV, Wirth S.

Gynecol Oncol. 1995 Aug;58(2):274-7.

PMID:
7622120
6.

Adenocarcinoma in situ of the cervix: management and outcome.

Azodi M, Chambers SK, Rutherford TJ, Kohorn EI, Schwartz PE, Chambers JT.

Gynecol Oncol. 1999 Jun;73(3):348-53.

PMID:
10366458
7.

Factors affecting residual lesion in women with cervical adenocarcinoma in situ after cone excisional biopsy.

Srisomboon J, Kietpeerakool C, Suprasert P, Siriaunkgul S, Khunamornpong S, Prompittayarat W.

Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):225-8.

8.

Conservative management of adenocarcinoma in situ of the cervix.

Shin CH, Schorge JO, Lee KR, Sheets EE.

Gynecol Oncol. 2000 Oct;79(1):6-10.

PMID:
11006022
9.
11.

Superficial (early) endocervical adenocarcinoma in situ: a study of 12 cases and comparison to conventional AIS.

Witkiewicz A, Lee KR, Brodsky G, Cviko A, Brodsky J, Crum CP.

Am J Surg Pathol. 2005 Dec;29(12):1609-14.

PMID:
16327433
12.

Adenocarcinoma in situ of the cervix.

Schoolland M, Segal A, Allpress S, Miranda A, Frost FA, Sterrett GF.

Cancer. 2002 Dec 25;96(6):330-7.

13.

Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study.

Cohen PA, Brand A, Sykes P, Wrede DCH, McNally O, Eva L, Rao A, Campion M, Stockler M, Powell A, Codde J, Bulsara MK, Anderson L, Leung Y, Farrell L, Stoyles P.

BMJ Open. 2017 Aug 28;7(8):e017576. doi: 10.1136/bmjopen-2017-017576.

14.

[Endocervical adenocarcinoma in situ. A histological entity to know].

Fignon A, Mayelo V, Wurst C, Magnin G, Tariel D, Descamps P, Renjard L, Body G, Lansac J.

J Gynecol Obstet Biol Reprod (Paris). 1995;24(4):369-73. Review. French.

PMID:
7650312
15.

Is conservative treatment for adenocarcinoma in situ of the cervix safe?

Soutter WP, Haidopoulos D, Gornall RJ, McIndoe GA, Fox J, Mason WP, Flanagan A, Nicholas N, Barker F, Abrahams J, Lampert I, Sarhanis P.

BJOG. 2001 Nov;108(11):1184-9.

16.

Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix.

Denehy TR, Gregori CA, Breen JL.

Obstet Gynecol. 1997 Jul;90(1):1-6.

PMID:
9207802
17.

The value of endocervical curettage as part of the standard colposcopic evaluation.

Granai CO, Jelen I, Louis F, Kawada CY, Curry SL.

J Reprod Med. 1985 May;30(5):373-5.

PMID:
4009557
18.

2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ.

Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D; 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference.

J Low Genit Tract Dis. 2007 Oct;11(4):223-39. Erratum in: J Low Genit Tract Dis. 2008 Jan;12(1):63.

PMID:
17917567
19.
20.

Artifact in cervical LLETZ specimens: correlation with follow-up.

Ioffe OB, Brooks SE, De Rezende RB, Silverberg SG.

Int J Gynecol Pathol. 1999 Apr;18(2):115-21.

PMID:
10202667

Supplemental Content

Support Center